Diego Alves, Laura Ceballos-Laita, Bruno Rizzuti, Krzysztof Pyrc, Sonia Vega, Luana Bagnoli, Eder J. Lenardão, Ana Jiménez-Alesanco, Pawel Botwina, David Ortega-Alarcon, Ornelio Rosati, Francesca Marini, Agnieszka Dabrowska, Francesca Mangiavacchi, Olga Abian, Adrián Velázquez-Campoy, Luca Sancineto, Anna Kula-Pacurar, Laura Abenante, Claudio Santi, Elena Menichetti, Sergio F. Fonseca, Università degli Studi di Perugia, Instituto de Salud Carlos III, Fundación hna, European Commission, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Ministerio de Economía y Competitividad (España), Diputación General de Aragón, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brasil), Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brasil), Financiadora de Estudos e Projetos (Brasil), Ministry of Science and Higher Education (Poland), Botwina, Pawel [0000-0001-9006-1568], Bagnoli, Luana [0000-0002-0622-4561], Marini, Francesca [0000-0003-0747-5060], Alves, Diego [0000-0002-1074-0294], Dabrowska, Agnieszka [0000-0003-1499-4950], Kula-Pacurar, Anna [0000-0001-8404-2176], Ceballos-Laita, Laura [0000-0002-7223-1719], Rizzuti, Bruno [0000-0003-1110-764X], Lenardão, Eder J. [0000-0001-7920-3289], Velázquez-Campoy, Adrián [0000-0001-5702-4538], Pyrc, Krzysztof [0000-0002-3867-7688], Sancineto, Luca [0000-0002-6199-7399], Santi, Claudio [0000-0002-7698-8970], Botwina, Pawel, Bagnoli, Luana, Marini, Francesca, Alves, Diego, Dabrowska, Agnieszka, Kula-Pacurar, Anna, Ceballos-Laita, Laura, Rizzuti, Bruno, Lenardão, Eder J., Velázquez-Campoy, Adrián, Pyrc, Krzysztof, Sancineto, Luca, and Santi, Claudio
The development of new antiviral drugs against SARS-CoV-2 is a valuable long-term strategy to protect the global population from the COVID-19 pandemic complementary to the vaccination. Considering this, the viral main protease (Mpro) is among the most promising molecular targets in light of its importance during the viral replication cycle. The natural flavonoid quercetin 1 has been recently reported to be a potent Mpro inhibitor in vitro, and we explored the effect produced by the introduction of organoselenium functionalities in this scaffold. In particular, we report here a new synthetic method to prepare previously inaccessible C-8 seleno-quercetin derivatives. By screening a small library of flavonols and flavone derivatives, we observed that some compounds inhibit the protease activity in vitro. For the first time, we demonstrate that quercetin (1) and 8-(p-tolylselenyl)quercetin (2d) block SARS-CoV-2 replication in infected cells at non-toxic concentrations, with an IC50 of 192 μM and 8 μM, respectively. Based on docking experiments driven by experimental evidence, we propose a non-covalent mechanism for Mpro inhibition in which a hydrogen bond between the selenium atom and Gln189 residue in the catalytic pocket could explain the higher Mpro activity of 2d and, as a result, its better antiviral profile, This work was supported by the University of Perugia “Fondo per la Ricerca di Base 2019”(C.S.); Fundación hna (to A.V.C. and O.A.); Miguel Servet Program from Instituto de Salud Carlos III (CPII13/00017 to O.A.); Fondo de Investigaciones Sanitarias from the Instituto de Salud Carlos III, and the European Union (ERDF/ESF, “Investing in your future”) (PI18/00349 to O.A. and an FIS Research Contract to L.C.L.); Spanish Ministry of Economy and Competitiveness (BFU2016-78232-P to A.V.C.); Spanish Ministry of Science, Innovation and Universities (FPI Predoctoral Research Contract BES-2017-080739 to D.O.A.); Diputación General de Aragón (Predoctoral Research Contract 2019 to A.J.A., “Protein Targets and Bioactive Compounds Group” E45_20R to A.V.C., “Digestive Pathology Group” B25_20R to O.A.); and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd). This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001. FAPERGS, CNPq, and FINEP are acknowledged for financial support. CNPq is also acknowledged for fellowships to E.J.L. and D.A. This work was supported by the subsidy from the Polish Ministry of Science and Higher Education for research on the